Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer

BACKGROUND: Treatment for stage III non‐small cell lung cancer (NSCLC) of unresectable disease mainly involves concurrent chemoradiation (CRT). Post‐CRT consolidation treatment with durvalumab is a major therapeutic advance that provides survival benefit in this group of patients. However, the perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Chia‐Hsun, Chiu, Tzu‐Hsuan, Wang, Chin‐Chou, Chang, Wen‐Chen, Huang, Allen Chung‐Cheng, Liu, Chien‐Ying, Wang, Chih‐Liang, Ko, Ho‐Wen, Chung, Fu‐Tsai, Hsu, Ping‐Chih, Guo, Yi‐Ke, Kuo, Chih‐Hsi S., Yang, Cheng‐Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262925/
https://www.ncbi.nlm.nih.gov/pubmed/32281272
http://dx.doi.org/10.1111/1759-7714.13426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262925/
https://www.ncbi.nlm.nih.gov/pubmed/32281272
http://dx.doi.org/10.1111/1759-7714.13426

Ejemplares similares